Prostate cancer immunotherapy. (4th May 2022)

• Record Type: Journal Article
• Authors: Mitsogiannis, Iraklis; Tzelves, Lazaros; Dellis, Athanasios; Issa, Hussein; Papatsoris, Athanasios; Moussa, Mohammad
• Is Part Of: Expert opinion on biological therapy. Volume 22:Number 5(2022)
• Page Start: 577
• Page End: 590
• Publication Date: 2022-05-04
• Subjects: Immunotherapy -- PARP inhibitors -- PD-1/PD-L1 inhibitors -- prostate cancer -- PSMA -- vaccines; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2022.2027904
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Introduction: Medical treatment for prostate cancer (PC) targets hormonal pathways used by malignant cells. Research advances aided in gaining knowledge about implicated molecular pathways and opened the way for establishment of new types of therapies by modifying immunological mechanisms. The aim of this review is to present completed and ongoing research projects regarding PC immunotherapy. Areas covered: A literature search was conducted in PubMed/MEDLINE, Scopus, Cochrane Central Register of Controlled Trials, and https://www.clinicaltrials.gov/ from inception until 07/2021, to identify completed or ongoing Phase III trials regarding several immunotherapies against PC. Studies on vaccine therapies, CTLA-4 inhibitors, PD-1/PD-L1 inhibitors, PARP inhibitors, PSMA-targeted therapies, and tyrosine kinase inhibitors were considered eligible. Expert opinion: Although many molecules are being tested against PC cells, only sipuleucel-T has gain approval in the USA. The main reason for this delay in establishing immunotherapy as a standard option for managing PC is the heterogeneity and tumor immune microenvironment complexities. Ipilimumab and olaparib were proved to prolong overall survival significantly against placebo, but a lot of research is going on to identify which patients and at what stage of disease will benefit the most before incorporating them in clinical practice. More recent options such as PSMA-targeted treatments are currently evaluated. Article Highlights: Intense research performed on immunotherapy for prostate cancer. Vaccine therapy with sipuleucel-T, the only approved immunotherapy for prostate cancer. Ipilimumab shows survival benefits. Olaparib shows survival benefits. Findings should be confirmed on further trials to identify target population characteristics and proper disease stage. Immunotherapy is not yet a standard due to tumor environment complex interaction between immune system and malignant cells.